Anti-CD19 chimeric antigen receptor T cell therapy - Wuhan Sian Medical Technology

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Wuhan Sian Medical Technology

Alternative Names: CD19 chimeric antigen receptor-modified T cell therapy - Wuhan Sian Medical Technology; CD19-CAR T cell therapy - Wuhan Sian Medical Technology

Latest Information Update: 22 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sian Wuhan Medical Technology
  • Developer Sian Wuhan Medical Technology; Wuhan Union Hospital
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 Apr 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater, Refractory metastatic disease) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top